JZP815
- Generic Name
- JZP815
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 332
- Registration Number
- NCT05557045
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Florida Cancer Specialists - Sarasota, Sarasota, Florida, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath